

Inpatient care of patients with type I diabetes mellitus by duration of diabetes and sex: A nationwide population-based longitudinal study

Markku J Akkanen^{1,4}
Sirikka-Liisa Kivelä²
Veli Koistinen³
Harri Sintonen⁴
Jaakko Tuomilehto⁴

¹Welfare and Health Promotion Division, Department of Chronic Disease Prevention, Diabetes Prevention Unit, National Institute for Health and Welfare (THL), Helsinki, Finland; ²Turku University of Central Hospital, Turku, Finland; ³Department of Health Policy and Management, University of Kuopio, Kuopio, Finland; ⁴Department of Public Health, University of Helsinki, Helsinki, Finland

Aims: To describe hospitalizations of a cohort of patients with type 1 diabetes mellitus (T1DM) during 1973–1998 in the main complication groups by sex and T1DM lasting on average 9.5 or 16.5 years.

Material and methods: The population (N = 5166) consisted of all Finnish patients with T1DM diagnosed before the age of 18 years between 1965–1979, derived from the Finnish population-based register of T1DM patients. Data on hospitalizations were obtained from the Finnish Hospital Discharge Register.

Results: In the early stages of T1DM, the majority of the use of hospitalizations was due to the treatment of T1DM without complications. Enormous increases were found for complications when diabetes lasted longer (from 9.5 to 16.5 years). For women, the yearly number of bed-days for renal complications increased 4.8-fold, for peripheral vascular disease 4.3-fold, and for ophthalmic complications 2.5-fold. For men, the corresponding increases were as follows: 5-fold, 6.9-fold, and 2.5-fold. The yearly number of bed-days for nephropathy increased 7-fold. Bed-days for T1DM without complications dropped dramatically. The length of stay in hospitalizations decreased notably, but hospital visits increased when the duration of T1DM increased.

Conclusions: Hospitalizations due to complications substantially increase with aging of T1DM patients. Prevention of T1DM is strongly needed.

Keywords: T1DM, inpatient care, hospitalizations, complications

Introduction

Diabetes has major long-term implications, not only for the health and well-being of individuals, but also for health services costs.¹ Diabetes may cause many complications, such as retinopathy, nephropathy, cardiac and cerebrovascular disease, and peripheral vascular disease with neuropathy, and the probability of developing these is related to the duration of diabetes and the metabolic control.² Diabetic ketoacidosis and severe hypoglycemia are acute complications that may be life-threatening.³ Patients with diabetes are also at increased risk for secondary complications, eg, influenza-associated respiratory illnesses.⁴ Inpatient hospital care is the major contributor to the health care costs of diabetes.^{5–9} In addition to glycosylated hemoglobin as a significant predictor of diabetes complications, urine albumin:creatinine ratio, body mass index, triglycerides, and high-density lipoproteins are independent predictors of hospitalizations for complications due to diabetes.¹⁰ Even a modest reduction in hospitalizations of people with diabetes could result in major savings;¹¹ hospitalization data are crucial in developing strategies for preventing hospitalizations.¹²

Correspondence: Markku J Akkanen
Department of Public Health, University of Helsinki, Helsinki, Finland; and National Institute for Health and Welfare (THL), Welfare and Health Promotion Division, Department of Chronic Disease Prevention, Diabetes Prevention Unit, PO Box 30, FI-00271 Helsinki, Finland
Tel +35 89 1912 7614
Fax +35 89 1912 7313
Email juho.akkanen@welho.com

As the burden of diabetes is increasing, it is vital to develop new prevention strategies and treatments. There have been several multicenter clinical trials designed to prevent type 1 diabetes mellitus (T1DM), which have tested nicotinamide, parenteral insulin, oral insulin, nasal insulin, and the elimination of cow's milk from infant feeding.¹³ These studies were aimed at preventing or delaying clinical T1DM, and have given certain hope that T1DM can be prevented, as new studies are emerging.^{13,14} Developing a vaccine for enterovirus is a new field of study, which looks promising in prevention of T1DM.¹⁴

In the studies conducted mainly in the United States, insulin analogs were noticed to offer a better balance between glycemic control and hypoglycemia when compared with human insulins, and the subsequent potential to reduce the costs of hospital treatments and chronic complications.¹⁵

In Finland, the incidence of T1DM is the highest in the world.^{16,17} Since the beginning of the 1990s, the incidence has increased, reaching 60 per 100,000 person-years in 2005.¹⁸ The medical and financial burden of diabetes will increase on the Finnish society, on the health care sector and on affected persons, as the number of patients with severe complications may rise. The need for health economic information, especially longitudinal, about T1DM will become more stressed.

In Finland, nationwide data on incident cases of childhood-onset diabetes exist since 1965.¹⁹ These data form a good basis for research into the epidemiology and health services utilization in patients with T1DM. The overall aim of this study was to describe the use of inpatient care of a cohort of childhood-onset diabetic patients prospectively during 1973 to 1998, especially in the main categories of diabetic complications.

Material and methods

The population consisted of all Finnish T1DM patients diagnosed before the age of 18 years between January 1st, 1965 and December 31st, 1979 and derived from the Finnish population-based register with patients with T1DM. At the end of 1979, this dynamic cohort consisted of 5,166 patients (2,327 females, 2,839 males).

The Finnish population-based register belongs to the material of the Diabetes Epidemiology Research International (DERI) Study, which has been used in evaluating mortality in T1DM.^{20–22} The register was established by linking the Finnish Hospital Discharge Register (FHDR) with the Social Insurance Institution Central Drug Register using the unique

personal identification numbers recorded in both registers. The Central Drug Registry only recorded the date of approval of the free-of-charge medication, so copies of the original certificates had been collected for the years 1965–1979 to obtain the actual dates of diagnosis.¹⁹ Data on hospitalizations were obtained from the FHDR.

Two cohorts were formed based on the duration of diabetes. The hospitalizations during two three-year periods of duration, 9–11 and 16–18 years, were compared in nine complication groups associated with diabetes.²³ The nine complication groups were the following: cerebrovascular disease, cardiac disease, peripheral vascular disease, neurological complications, renal complications, endocrine complications, ophthalmic complications, other complications, and coma. The complications and complication groups were based on the criteria of the American Diabetes Association.²⁴ Cerebrovascular complications were extracted from neurological disorders. Diabetic coma was included as a separate group. The main diagnosis of each hospitalization was used in calculations. Hospitalizations in nine complication groups were compared between these two three-year periods (9–11 and 16–18 years). Hospitalizations were first calculated for these three-year periods and then divided by three, indicating the effect of duration on hospitalizations when diabetes had lasted on average 9.5 years compared with 16.5 years. The amount of hospitalizations due to each complication group was compared with the amount of use due to all complications, hospitalizations due to other causes than diabetes, and hospitalizations due to all hospitalizations (due to any cause). Diabetes-related hospitalizations due to diabetic complications, and without complications (International Code of Diseases [ICD]: ICD-8 code 25000 and ICD-9 code 2500B) were also calculated separately. The results were presented by ICD-9 codes, and ICD-8 codes were converted to correspond to ICD-9 codes, because the coding changed in 1987. ICD-10 was officially adopted on January 1st, 1996 in Finland (the first edition was published in 1995 and the second one in 1998). The ICD-10 codes for diabetes in FHDR changed markedly compared to the earlier versions (ICD-8 and ICD-9) and if this study could have used ICD-10 codes, another translation of the codes would have been needed, which would have complicated and biased the study too much.

The exact dates of death were used when calculating the number of patients alive (N1) in the beginning and at the end (N2) of the two periods, and then summed and divided by 2 (N1+N2/2) in order to obtain the average number of people

alive during the two study periods. The average number of patients was 5,120 in the 9.5-year cohort and 5,010 in the 16.5-year cohort. These figures were used in calculating bed-days and discharges per 1,000 patients.

The following principles were applied in calculations:

- If there were two days or less between two treatment periods, they were defined as two different treatment periods if the main diagnoses of the periods were different. If the main diagnoses of the periods were the same, the periods were defined as one treatment period.
- The days of admission to hospital and discharge from hospital were treated as a single bed-day.
- Overlapping treatment periods of the same patient in two different locations were either errors or due to specific consultations and thus the overlapping part was omitted in order to avoid overestimation of bed-days.
- Discharge (treatment period): Hospitalization period lasting for at least 15 hours.
- Average length of stay (LOS): The number of hospital days divided by the number of treatment periods (discharges).
- Bed-days per user: The number of bed-days divided by the number of patients who used hospital at least once during the period concerned.
- As pregnancy is not a disease, hospitalizations due to pregnancies were omitted, eg, for comparison purposes (men/women).

Results

The mean age at diagnosis in the cohort was 10.3 years (standard deviation [SD] 4.4; min 0.7 and max 17.9). When the average duration of diabetes was 9.5 or 16.5 years, the mean ages of patients were 20 years (min 10; max 27.5) and 27 years (min 17; max 34.5), respectively. Hospitalizations occurred between 1973–1998, follow-up being 26 years. The number of hospital users are shown in Table 1.

Bed-days for total population

In the 9.5-year cohort, the shares of bed-days of other complications, ophthalmic complications, renal complications and coma were the biggest, and their shares of the total amount of bed-days were 6.0%, 3.6%, 2.2%, and 1.5%, respectively.

In the 16.5-year cohort other, renal, ophthalmic and peripheral vascular complications constituted the biggest shares of the amount of bed-days of all complications. Especially renal, but also peripheral vascular and cardiovascular complications showed the biggest increases in shares compared with the 9.5-year cohort, while the shares of other complications and coma dropped clearly. The shares of other, renal, ophthalmic and peripheral vascular complications of the total amount of bed-days were 15.0%, 12.1%, 11.3%, and 3.0%, respectively. The share of the first four complication groups combined (cerebrovascular, cardiovascular, peripheral vascular, and neurological complications) increased from 1.3% to 5.5%.

Table 1 Number of hospital users during the periods of three years by sex and duration of diabetes (by complication groups, complications combined, T1DM without complications and total number)

	No. of females		No. of males		No. of females		No. of males	
	T1DM		T1DM		T1DM		T1DM	
	9–11 yrs.	9–11 yrs.	16–18 yrs.	16–18 yrs.	9–11 yrs.	16–18 yrs.	9–11 yrs.	16–18 yrs.
CERVASC	3	2	7	3	5	10		
CARVASC	2	7	8	15	9	23		
PERVASC	11	12	60	53	23	113		
NEUROL	11	18	32	25	29	57		
RENAL	47	33	173	107	80	280		
ENDOCRIN	0	0	0	1	0	1		
OPHTHALMIC	104	77	271	230	181	501		
OTHER complicat.	112	122	166	164	234	330		
COMA	45	38	18	32	83	50		
Complications total	295	274	555	495	569	1050		
2500B/25000	1106	1042	469	457	2148	926		
TOTAL use	1349	1378	1213	1171	2727	2384		

Abbreviations: Cervasc, cerebrovascular disease; carvasc, cardiac disease; pervasc, peripheral vascular disease; neurol, neurological complications; renal, renal complications; endocrin, endocrine complications; ophthalmic, ophthalmic complications; 2500B/25000, T1DM without complications (ICD-9/ICD-8 codes).

The total yearly number of bed-days used due to complications during the first and second three-year periods increased from 6,742 to 18,158 days, while the number of bed-days used due to any cause decreased from 45,986 to 40,669 days. The share of the bed-days of the nine complication groups of the total amount of bed-days rose from 14.7% to 44.6%. The number of bed-days due to diabetes without complications dropped by 73%.

As calculated by the mean numbers of yearly bed-days per 1,000 patients by the complication group and the duration of diabetes, other complications remained the biggest complication group when the duration of diabetes increased, while renal diseases replaced ophthalmic diseases as the second biggest group. Hospitalizations due to cardiovascular (+1,406%), peripheral vascular (+474%), renal (+387%), ophthalmic (+185%), cerebrovascular (+131%), other (+126%) and neurological (+52%) complications increased. Endocrine complications were practically nonexistent. Bed-days due to coma decreased by 54%.

Bed-days by sex

Female patients had a bigger share of bed-days due to ophthalmic complications than men while male patients had a bigger share due to other complications in the 9.5-year cohort (Figure 1). In the 16.5-year cohort female patients had a bigger share of bed-days due to renal complications while male patients had a bigger share due to peripheral complications. The biggest change in the shares of bed-days of any complication group was the increases in shares of renal complications in both sexes.

Female patients used more bed-days per 1,000 patient-years than males; in the 9.5-year cohort for all hospitalizations 39% more and in the 16.5-year cohort 32% more than males, and for hospitalizations due to complications 32% and 30% more, respectively. Female patients had used almost twice more bed-days (per 1,000 patient-years) due to ophthalmic complications than males in the 9.5-year cohort and 47% more in the 16.5-year cohort, and 60% more yearly bed-days due to renal complications in the 9.5-year cohort and 55% more in the 16.5-year cohort. Male patients had used 52% more yearly bed-days due to peripheral vascular complications when diabetes lasted longer. The number of bed-days due to coma dropped more in female than male patients.

There were marked increases in the yearly number of bed-days due to certain complications when diabetes had lasted longer. From the 9.5-year cohort to the 16.5-year cohort, the number of bed-days due to renal complications




Figure 1 Percentages of yearly bed-days due to complications out of all bed-days due to complications by complication group, duration of type 1 diabetes (T1DM) and sex.

Abbreviations: Cervasc, cerebrovascular disease; Carvasc, cardiac disease; Pervasc, Peripheral vascular disease; neurol, neurological complications; renal, renal complications; endocrin, endocrin complications; ophthalmic, ophthalmic complications; other, other complications.

increased 4.8-fold, peripheral vascular complications 4.3-fold, neurological complications 3.2-fold, ophthalmic complications 2.5-fold, and other complications 2.3-fold in female patients. In male patients, the number of bed-days due to peripheral vascular complications increased 6.9-fold, renal complications 5-fold, ophthalmic complications 3.4-fold, and other complications 2.2-fold.

Length of stay

In all complication groups combined there was a drop in average length of stay (LOS) from 7.7 (SD 8.1) to 6.9 days (SD 9.2), and LOS for total inpatient care (for any cause) dropped from 7.4 (SD 10.3) to 6.4 days (SD 19.2), as the duration of diabetes increased by seven years. Generally, male patients seemed to have stayed slightly longer in hospital during their treatment periods than females. Among both sexes, LOS for many complications seemed to decrease, and LOS due to ophthalmic complications and coma had a clear drop among both sexes (1.7 to 1.9 days), as did LOS due to renal complications among female patients (8.9 to 7.1 days). LOS due to cardiovascular complications increased in both sexes, and LOS due to cerebrovascular complications

increased in women, but decreased in men. The number of patients in these two groups however was small.

Most common diagnoses

Regarding total inpatient care, diabetes without complications was a dominating diagnosis when diabetes had lasted 9–11 years, representing 61% of all bed-days and 71% of bed-days due to other causes than complications (Table 2). The number of bed-days due to the treatment of diabetes without complications was 4.2-fold that due to the treatment of complications when diabetes had lasted 9–11 years. Its share dropped by 73%, when the duration of diabetes increased by seven years. The number of bed-days for treating diabetic nephropathy showed a seven-fold rise when the duration of diabetes increased.

The number of bed-days for treating all other defined complications, ophthalmic complications and retinopathy increased over 3-fold, while the number of bed-days for treating nondefined complications decreased 63% when diabetes lasted longer.

Treatment of mental diseases and disorders (eg, various personality disorders, schizophrenia, and depression) seemed to cause a large number of bed-days and long treatment periods. Measured by the number of bed-days and discharges, ketoacidosis, diabetic microangiopathy, diabetic neuropathy, and coma were among the most common diagnoses in the cohort with a longer duration of diabetes. The changes in the number of bed-days during the two three-year periods relating to certain diagnoses of ophthalmic complications turned out to be interesting. The number of bed-days due to treatment of glaucoma was 8-fold and that due to treatment of diabetic retinopathy 2.7-fold in the 16.5-year cohort compared with the 9.5-year cohort.

Discussion

Drug treatment for diabetes is free of charge in Finland. Patients receive reimbursement from the Social Insurance Institution after the institution has approved the application based on a certificate from the physician. Only occasionally the parents of a diabetic child fail to seek reimbursement for insulin costs, and the child is not included in the nationwide Central Drug Registry. The ascertainment rate of childhood diabetes is almost 100%;¹⁹ the case ascertainment in this cohort was virtually complete.^{19,25}

In Finland, there are better possibilities to conduct register-based health studies than in most other countries, as the coverage of registers is good and their quality for research purposes is excellent. It is possible to link registers with a

personal identification code.²⁶ The accuracy and quality of the FHDR data for epidemiological research purposes have been estimated.^{26–31} In a comparison of coded diagnoses with hospital records during the corresponding hospital stay, 95% of the main diagnoses and 96% of the dates of admission and discharge were correct in 1986.

The main diagnoses of hospital discharges were compared. Thus, the inferior accuracy of the secondary diagnoses in FHDR had no relevance. The use of primary diagnosis also prevented double counting, that can happen when multiple diagnoses are used.

Hospitalizations after diabetes durations of 9–11 and 16–18 years were compared. The hospitalizations were first considered in three-year periods to obtain steadier frequencies across years and to damp fluctuations. These three-year numbers were divided by three to get yearly figures and to demonstrate how hospital use differs in complication groups when diabetes has lasted on average 9.5 years compared with 16.5 years. Yearly inpatient care was calculated per 1,000 patients to adjust for different numbers of men and women and to take into account mortality.

Ketoacidosis and hypoglycemia have ICD-9 codes, but not ICD-8 codes. Their inclusion in complication grouping would have distorted the comparisons so they were excluded from the main groupings. Physicians in hospital may have coded these into secondary diagnoses, or most likely into group other complications (diabetes with other specified/unspecified complications; Table 2). This is supported by the fact, that besides the number of bed-days, number of hospital users also clearly increased in that group (Table 1).

The lack of ICD-8 codes for microangiopathy may have caused an underestimation of peripheral vascular complications in the younger group, and an overestimation of the growth as diabetes lasted longer.

No hospital periods exceeding 365 days existed in hospital use for any complication group during the two three-year observation periods; very long hospital periods (“outliers”) did not affect the results. Only a few shorter outliers were observed, which raised the means of bed-days in certain groups and observation periods.

Hospital use due to complications increased markedly; the numbers of hospital users doubled, the annual number of discharges increased 3-fold and that of bed-days 2.8-fold when diabetes lasted longer.

With increasing duration of diabetes, the length of stay decreased in all complication groups, except in cerebrovascular, cardiovascular, and peripheral vascular complications. Although the LOS in hospital generally

Table 2 Number of bed-days and discharges, and mean length of stay (LOS) of diseases (by diagnoses) causing most inpatient care in complication groups (ranked by the amount of bed-days) and for total use in the two observation period of three years of T1DM duration

T1DM duration 9–11 years				T1DM duration 16–18 years			
Bed-days	Discharges	LOS	Diagnosis	Bed-days	Discharges	LOS	Diagnosis
Total hospital use							
28045	3856	7.3	Diabetes without complications	7711	1539	5.0	Diabetes without complications
1801	229	7.9	Diabetes with other specified complications	5707	644	8.9	Diabetes with other specified complications
1345	185	7.3	Diabetes with ophthalmic complications + retinopathy	4262	537	7.9	Diabetic nephropathy
1048	20	52.4	Anxiety dissociative and somatoform disorders	4012	756	5.3	Diabetes with ophthalmic complications + retinopathy
749	76	9.9	Diabetes with unspecified complication	1978	6	329.7	Schizophrenic disorders
696	106	6.6	Diabetes with hyperosmolarity	1310	43	30.5	Personality disorders
643	9	71.4	Schizophrenic disorders	609	141	4.3	Diabetes with ketoacidosis
609	74	8.2	Diabetic nephropathy	551	111	5.0	Microangiopathy
602	15	40.1	Personality disorders	431	25	17.2	Multiple sclerosis
347	72	4.8	Diabetes with ketoacidosis	385	59	6.5	Diabetic neuropathy
345	4	86.3	Episodic mood disorders	317	13	24.4	Rheumatoid arthritis specified
				312	65	4.8	Diabetes with hyperosmolarity
Cerebrovascular complications							
30	1	30.0	Cerebral embolism	96	5	19.2	Cerebral thrombosis
19	2	9.5	Transient cerebral ischemia	38	1	38.0	Other cerebrovascular disorders
16	1	16.0	Intracerebral hemorrhage	13	3	4.3	Transient ischemic attack
Cardiovascular complications							
8	3	2.7	Atrial fibrillation	133	13	10.2	Acute myocardial infarction
7	2	3.5	Old myocardial infarction	75	2	37.5	Congestive heart failure
4	3	1.3	Other specified cardiac dysrhythmias	72	8	9.0	Old myocardial infarction
				24	2	12.0	Congestive heart failure/pulmonary edema
				31	2	15.5	Unstable angina pectoris
Peripheral vascular complications							
90	11	8.2	Microangiopathy	547	109	5.0	Microangiopathy
58	7	8.3	Chronic ulcer of other specified/unspecified sites	142	9	15.8	Chronic ulcer in other specified/unspecified sites
23	3	7.7	Traumatic amputation of thumb complicated	117	7	16.7	Chronic ulcer
16	1	16.0	Peripheral vascular disease unspecified	73	10	7.3	Diabetic gangrene
16	2	8.0	Phlebitis and thrombophlebitis	70	5	14.0	Ulcer in lower leg
Neurological complications							
273	36	7.6	Diabetic neuropathy	385	59	6.5	Diabetic neuropathy
				28	20	1.4	Carpal tunnel syndrome
				10	4	2.5	Peripheral nerve disorder Median nerve

(Continued)

Table 2 (Continued)

T1DM duration 9–11 years				T1DM duration 16–18 years			
Bed-days	Discharges	LOS	Diagnosis	Bed-days	Discharges	LOS	Diagnosis
Renal complications							
609	74	8.2	Diabetic nephropathy	4262	537	7.9	Diabetic nephropathy
199	19	10.5	Renal infection/Acute pyelonephritis	301	54	5.6	Renal infection. Acute pyelonephritis
124	9	13.8	Renal infection/Chronic pyelonephritis	164	14	11.7	Other disease of urinary tract
27	4	6.8	Renal infection unspecified	64	6	10.7	Renal infection. Chronic pyelonephritis
26	2	13.0	Acute nephritis	43	8	5.4	Chronic nephritis with uremia
Endocrine complications							
–	–	–	–	3	1	3.0	Hyperkalemia
Ophthalmic complications							
1174	153	7.7	Diabetic retinopathy	3143	566	5.6	Diabetic retinopathy
171	32	5.3	Diabetes with ophthalmic complications	739	174	4.2	Diabetes with ophthalmic complications
93	12	7.8	Diabetic cataract	250	50	5.0	Glaucoma
41	9	4.6	Acute iridocyclitis	137	27	5.1	Diabetic cataract
66	9	7.3	Cataract	95	6	15.8	Diabetes with other specified ophthalmic complications
31	8	3.9	Glaucoma	80	22	3.6	Cataract
27	3	9.0	Iridocyclitis chronic uveitis	72	10	7.2	Hemorrhage of vitreous body
Other complications							
1640	230	7.1	Diabetes with other specified complications	5689	642	8.9	Diabetes with other specified complications
872	78	11.2	Diabetes with unspecified complications	277	57	4.9	Diabetes with unspecified complications
115	13	8.8	Cellulitis. Cutaneous/subcutaneous infections	66	6	11.0	Chronic osteomyelitis
77	3	25.7	Chronic osteomyelitis	17	4	4.3	Cellulitis. Cutaneous/subcutaneous infections

decreased, the number of discharges per user increased, especially for other, renal, and ophthalmic complications; patients were more frequently in hospital. The number of bed-days per user for complication groups increased because the drop of the LOS was offset by the increase in the frequency of hospital visits. More patients without complications may have been treated in outpatient care and at home as a result of a change in treatment practices and a rise in patients' age.

Generally, women used clearly more inpatient treatment than men. One explanation may be that women seek health care more readily than men, which has been reported earlier.^{32,33} Men's attitudes towards diseases and symptoms are different compared with those of women's, which may lead to men's slower reaction to seek health care.³⁴

As diabetes lasted longer, men had a slightly bigger increase than women in the hospital use due to all complications and in the total hospital use, as measured by the number of discharges, and in the hospital use due to all complications, as measured by the number of bed-days. Women's total number of bed-days dropped slightly more than that of men. Women visited hospitals slightly more frequently than men, when total hospital use and hospital use due to other causes than diabetes were observed. Men generally stayed during their treatment periods a bit longer in hospital than women, especially considering the group of complications combined, other hospitalizations than those due to diabetes and total hospitalizations, when diabetes had lasted 9.5 years or 16.5 years; the LOS decreased for

both sexes by about the same amount. The yearly numbers of bed-days and discharges per user considering all complications combined increased for both sexes clearly as the duration increased.

An increase in the proportion of yearly discharges due to renal complications was notably bigger for women than for men as the duration of diabetes increased, but for ophthalmic complications, men had a clearly bigger increase. The sex difference in yearly discharges was about the same in the 9.5-year cohort for ophthalmic complications as in the 16.5-year cohort for renal complications. Thus, women used hospital relatively more frequently due to ophthalmic causes than men when diabetes had lasted on average 9.5 years, but they visited hospital relatively more often for renal causes than men when the duration increased. The biggest differences between the sexes in the absolute number of discharges per 1,000 patients per year were that women had twice as much ophthalmic and over 50% more renal complication discharges when diabetes had lasted 9.5 years, and almost 40% more ophthalmic and twice as much renal complication discharges compared with men, when diabetes lasted longer.

In both sexes, the share of renal complications showed a considerable increase, replacing ophthalmic ones as the second biggest group with the increased duration. The share of yearly bed-days of ophthalmic complications dropped in women but rose in men. Women used clearly more bed-days for ophthalmic causes than men when diabetes had lasted on average 9.5 years, but the difference leveled off when diabetes lasted longer. The most striking sex differences considering the absolute number of yearly bed-days per 1,000 patients were that women had twice as many ophthalmic and 60% more renal complication discharges when diabetes had lasted 9.5 years, and around 50% more ophthalmic and renal complication bed-days compared to men when diabetes had lasted longer.

In terms of bed-days and discharges, men had a higher proportion in the complication group “other” than women also as the duration increased. This suggests that men were more prone to be given diagnoses “other defined” or “nondefined” complications and exact diagnoses were for some reason more seldom for men than for women.

There were vast increases in the yearly numbers of bed-days due to certain complications as the duration increased. These stress the importance of good metabolic control and management.

Hospitalizations due to endocrine complications was practically nonexistent. The small numbers of cerebrovascular

bed-days was surprising. These complications possibly evolve later, and should be examined in longer periods of durations of T1DM, than this study gave possibilities (although the follow-up period was 26 years).

The number of bed-days due to neurological complications increased in women, but decreased in men, as the duration of diabetes increased. That is partly explained by the fact that the number of female users increased 3-fold while the number of male users increased by 40%.

The occurrence of infectious complications might seem low. We studied hospitalizations, and many patients with infectious complications are treated as outpatients. This is the main reason for the low occurrence of infectious complications.

Also, infectious complications were spread among certain complication groups: renal complications (renal infections), peripheral vascular complications (microangiopathy, chronic ulcers etc.), and other complications. We did not want to present infections as an own group (as the grouping was mainly based on the criteria by American Diabetes Association).

The study has some limitations. No nondiabetic control group was used. Using a control group could have allowed the incremental effect of diabetes on hospitalizations to be shown. Due to difficulties in obtaining a valid and reliable control group, and due to limited resources and the scope of the study, the use of a control group was omitted. The primary diagnosis of hospital use was used to avoid double counting. This may have caused an underestimation of hospitalizations, as diabetes is often a contributory cause and is marked as a secondary diagnosis in hospital records, and they are not systematically recorded. This study was population-based, as the study population consisted of all Finnish patients with T1DM diagnosed before the age of 18 years (between 1965–1979). The study type was designed to be descriptive, not predictive or explanatory, and the main objective was to describe how hospital use changed during a long follow-up period. The data were formed by linking registers. The register data included only few variables about the population, and the possibilities to perform multivariate analyses to control possible confounding variables were small. This is why statistical modeling was not used.

For decision makers, especially in health care, it is important to know how diseases, eg, diabetes and its complications evolve as the duration increases in a long run, to help allocating resources in planning health care. We believe that this study gives more information, eg, for

that purpose, as studies similar to this are extremely rare, practically nonexistent, especially by sex.

Conclusions

As the duration of T1DM increased from 9.5 to 16.5 years on average, the yearly numbers of bed-days due to all complications of diabetes almost tripled, while the yearly numbers of bed-days due to diabetes without complications dropped considerably. The numbers of bed-days due to renal complications, peripheral vascular diseases, and ophthalmic complications increased markedly. Women consumed clearly more bed-days than men, especially due to renal and ophthalmic complications. By preventing and delaying complications, some resources devoted to treating persons with diabetes might be allocated to treatment of other diseases, or other purposes. Additionally, extra life-years and quality of life gains should be achieved.

Acknowledgments

The authors thank Valma Harjutsalo and especially project secretary Selena Nitecki for their valuable contribution.

Disclosure

The study (part of academic PhD dissertation by corresponding author), later edited numerous times, was supported financially by the following organizations and foundations: Yrjö Jahnsson Foundation, Jenny and Antti Wihuri Foundation, Onni ja Hilja Tuovinen Foundation, Unit of Family Medicine at the Turku University Central Hospital, Academy of Finland, Diabetes Prevention Unit of National Institute for Health and Welfare (formerly known as Diabetes Unit of National Public Health Institute), Department of Public Health at the University of Helsinki, National School of Social and Health Administration and Economics at the University of Kuopio, Oskar Öflund Foundation, Finnish Diabetes Association.

The authors declare that they have no conflict of interest. All authors meet the criteria for authorship stated in the Uniform Requirements for Manuscripts Submitted to by Medical Journal. The manuscript includes some results that have been reported in an academic PhD dissertation of the corresponding author (monograph, 219 pages) in Finland and web at the University of Helsinki in October 2007. The monograph was published in the series of National Public Health Institute which has approved the publication of the results. The present manuscript has been edited several times by authors after the dissertation. The basic results have not been changed.

References

1. Leese B. The cost of diabetes and its complications. *Soc Sci Med.* 1992;35:1303–1310.
2. Currie CJ, Williams DR, Peters JR. Patterns of in and outpatient activity for diabetes. A district survey. *Diabet Med.* 1996;13:273–280.
3. Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. *JAMA.* 2002;287:2511–2518.
4. Orzech EA, Nianwen S, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. *Clin Ther.* 2007;29:2246–2255.
5. Jönsson B. Diabetes – the cost of illness and the cost of control. *Acta Med Scand.* 1983;671(Suppl.1):19–27.
6. American Diabetes Association. *Direct and indirect costs of diabetes in the United States in 1992.* Alexandria, VA: American Diabetes Association; 1993.
7. Kangas T, Aro S, Koivisto VA, Salinto M, Laakso M, Reunanen A. Structure and costs of health care of diabetic patients in Finland. *Diabetes Care.* 1996;19:494–497.
8. American Diabetes Association. Economic consequences of diabetes mellitus in the USA in 1997. *Diabetes Care.* 1998;21:296–309.
9. American Diabetes Association. Economic costs of diabetes in the US in 2007. *Diabetes Care.* 2008;31:1–20.
10. Tomlin AM, Dovey SM, Tilyard MW. Risk factors for hospitalization due to diabetes complications. *Diabetes Res Clin Pract.* 2008;80:244–252.
11. Moss SE, Klein R, Klein BE. Risk factors for hospitalisation in people with diabetes. *Arch Intern Med.* 1999;159:2053–2057.
12. Fishbein H. Precipitants of hospitalisation in insulin-dependent diabetes mellitus (IDDM): A statewide perspective. *Diabetes Care.* 1982;8(Suppl1):61–64.
13. Skyler JS; Type 1 Diabetes TrialNet Study Group. Update on worldwide efforts to prevent type 1 diabetes. *Ann N Y Acad Sci.* 2008;1150:190–196.
14. Knip M. Tyypin 1 diabeteksen ehkäisy. Tutkimukset kasvattavat toiveita. *Diabetes ja lääkäri.* 2007;36:7–12.
15. Brixner DI, McAdam-Marx C. Cost-effectiveness of insulin analogs. *Am J Manag Care.* 2008;14:766–775.
16. Karvonen M, Tuomilehto J, Libman I, LaPorte R. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus: World Health Organization DIAMOND Project Group. *Diabetologia.* 1993;36:883–892.
17. Karvonen M, Pitkaniemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. *Diabetes Care.* 1999;22:1066–1070.
18. Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. *Lancet.* 2008;371:1777–1782.
19. Tuomilehto J, Rewers M, Reunanen A, et al. Increasing trend in Type 1 (insulin dependent) diabetes mellitus in childhood in Finland. Analysis of age, calendar time and birth cohort effects during 1965–1984. *Diabetologia.* 1991;34:282–287.
20. Major cross-country differences in risk of dying for people with IDDM. Diabetes Epidemiology Research International Mortality Study Group. *Diabetes Care.* 1991;14:49–54.
21. International evaluation of cause-specific mortality and IDDM. Diabetes Epidemiology Research International Mortality Study Group. *Diabetes Care.* 1991;14:55–60.
22. Asao K, Sarti C, Forsen T, et al. Long-term mortality in nationwide cohorts of childhood-onset T1DM in Japan and Finland. *Diabetes Care.* 2003;26:2038–2042.
23. Akkanen MJJ. *Inpatient hospital care and its costs among type 1 diabetic patients in Finland – a nationwide longitudinal study.* Dissertation, A11/2007. Helsinki, Finland: Publications of the National Public Health Institute; 2007.
24. American Diabetes Association. Economic consequences of diabetes mellitus in the USA in 1997. *Diabetes Care.* 1998;21:296–309.

25. Lounamaa R. *Mortality in Finnish patients with insulin-dependent diabetes mellitus. A follow-up study of patients diagnosed when under twenty years of age.* Dissertation, ML:126. Helsinki, Finland: Publications of Social Insurance Institution; 1993.
26. Keskimäki I, Salinto M, Koskinen S. Viranomaisrekisterit terveyden ja terveystalvelujen käytön tutkimusaineistona. *Suomen Lääkäri.* 1997;52:585–591.
27. Keskimäki I, Aro S. Accuracy of data on diagnoses, procedures and accidents in the Finnish Hospital Discharge Register. *Int J Health Sci.* 1991;2:15–21.
28. Mähönen M, Salomaa V, Brommels M, et al. The validity of hospital discharge register data on coronary heart disease in Finland. *Eur J Epidemiol.* 1997;13:403–415.
29. Nikiforov O. *Yleissairaanhoito Suomessa 1960- ja 1970-luvulla.* Helsinki, Finland: Lääkintöhallituksen tutkimuksia. 1984;32.
30. Salmela R, Koistinen V. Yleissairaaloitten poistoilmoitusrekistereiden kattavuus ja luotettavuus. *Sairaala.* 1987;49:480–482.
31. Niemi M, Winell K. *Diabetes Suomessa. Esiintyvyys ja hoidon laadun vaihtelu.* Helsinki, Finland: Stakes: Raportteja 8/2005;2005.
32. Kokko S. *Tauti ja sairaus – työikäiset terveyskeskuslääkärin vastaanotolla.* Kuopio, Finland: Kansanterveystieteen ja yleislääketieteen laitos: Kuopion yliopisto; 1988.
33. Hujanen T, Mikkola H, Pekurinen M, Häkkinen U, Teitto E. *Terveydenhuollon menot ikä- ja sukupuoliryhmittäin vuonna 2002.* Helsinki, Finland: Stakes: Aiheita 24/2004;2004.
34. Kivelä S-L. Miehen asennoituminen sairauteen: Mies ja terveys. *Leiraksen julkaisuja.* 1990;47:19–25.

Risk Management and Healthcare Policy

Publish your work in this journal

Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy, and preventative measures to promote good health and improve morbidity and mortality in the population. The journal welcomes submitted papers covering original research, basic science, clinical & epidemio-

logical studies, reviews and evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/risk-management-and-healthcare-policy-journal>

Dovepress